Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -27.35% is 34% above its 5-year average of -41.24%, near the high end of its 5-year range (-73.12%–-22.98%).
34.53% above its 12-month average of -41.78%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.52%.
RETURN ON ASSETS (ROA)
-27.35%
RETURN ON ASSETS (ROA) AVG TTM
-41.78%
RETURN ON ASSETS (ROA) AVG 3Y
-34.97%
RETURN ON ASSETS (ROA) AVG 5Y
-41.24%
RETURN ON ASSETS (ROA) AVG 10Y
-39.03%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+34.53%
CURRENT VS 3Y AVG
+21.79%
CURRENT VS 5Y AVG
+33.69%
CURRENT VS 10Y AVG
+29.93%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-1.67%
vs the sector median at left
Celcuity Inc.
Market Cap
$3.59B
Return on Assets (ROA)
-27.35%
TTM Avg
-41.78%
3Y Avg
-34.97%
5Y Avg
-41.24%
Market Cap
$3.58B
Return on Assets (ROA)
-1.28%
TTM Avg
-8.27%
3Y Avg
-17.73%
5Y Avg
-16.90%
Market Cap
$3.61B
Return on Assets (ROA)
20.83%
TTM Avg
2.76%
3Y Avg
-12.34%
5Y Avg
-9.97%
Market Cap
$3.62B
Return on Assets (ROA)
-13.36%
TTM Avg
-17.34%
3Y Avg
-16.80%
5Y Avg
-15.30%
Market Cap
$3.44B
Return on Assets (ROA)
21.83%
TTM Avg
22.04%
3Y Avg
-0.21%
5Y Avg
-10.13%
Market Cap
$3.25B
Return on Assets (ROA)
-11.64%
TTM Avg
-24.55%
3Y Avg
-30.16%
5Y Avg
-27.23%
Market Cap
$3.16B
Return on Assets (ROA)
-44.17%
TTM Avg
-37.77%
3Y Avg
-27.61%
5Y Avg
-21.12%
Market Cap
$4.03B
Return on Assets (ROA)
0.76%
TTM Avg
-1.39%
3Y Avg
-1.28%
5Y Avg
0.88%
Market Cap
$3.15B
Return on Assets (ROA)
5.84%
TTM Avg
-21.93%
3Y Avg
-47.49%
5Y Avg
-47.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celcuity Inc. (CELC) | $3.59B | -27.35% | -41.78% | -34.97% | -41.24% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.58B | -1.28% | -8.27% | -17.73% | -16.90% |
| CareDx, Inc (CDNA)vs › | $3.61B | 20.83% | 2.76% | -12.34% | -9.97% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.62B | -13.36% | -17.34% | -16.80% | -15.30% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 21.83% | 22.04% | -0.21% | -10.13% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | -11.64% | -24.55% | -30.16% | -27.23% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -44.17% | -37.77% | -27.61% | -21.12% |
| ICU Medical, Inc. (ICUI)vs › | $4.03B | 0.76% | -1.39% | -1.28% | 0.88% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 5.84% | -21.93% | -47.49% | -47.67% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -57.49% | -99.67% | -60.13% | -103.92% |
ROA
-27.4%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.95% |
| 2024-12-31 | -45.60% |
| 2023-12-31 | -33.35% |
| 2022-12-31 | -22.98% |
| 2021-12-31 | -34.46% |
| 2020-12-31 | -73.12% |
| 2019-12-31 | -36.29% |
| 2018-12-31 | -28.74% |
| 2017-12-31 | -19.56% |
| 2016-12-31 | -54.65% |
| 2015-12-31 | -42.67% |
